SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Veru Inc. – ‘10-Q’ for 3/31/19 – ‘EX-101.CAL’

On:  Wednesday, 5/15/19, at 1:21pm ET   ·   For:  3/31/19   ·   Accession #:  863894-19-7   ·   File #:  1-13602

Previous ‘10-Q’:  ‘10-Q’ on 2/13/19 for 12/31/18   ·   Next:  ‘10-Q’ on 8/8/19 for 6/30/19   ·   Latest:  ‘10-Q’ on 5/8/24 for 3/31/24   ·   5 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/15/19  Veru Inc.                         10-Q        3/31/19   72:6.7M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    670K 
 2: EX-10.1     Material Contract                                   HTML     75K 
 3: EX-10.3     Material Contract                                   HTML     74K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
13: R1          Document And Entity Information                     HTML     45K 
14: R2          Condensed Consolidated Balance Sheets               HTML    121K 
15: R3          Condensed Consolidated Balance Sheets               HTML     38K 
                (Parenthetical)                                                  
16: R4          Condensed Consolidated Statements Of Operations     HTML     79K 
17: R5          Condensed Consolidated Statements Of Stockholders?  HTML     68K 
                Equity                                                           
18: R6          Condensed Consolidated Statements Of Cash Flows     HTML    105K 
19: R7          Basis of Presentation                               HTML     70K 
20: R8          Liquidity                                           HTML     24K 
21: R9          Fair Value Measurements                             HTML     56K 
22: R10         Accounts Receivable and Concentration of Credit     HTML     62K 
                Risk                                                             
23: R11         Balance Sheet Information                           HTML     68K 
24: R12         Intangible Assets and Goodwill                      HTML     79K 
25: R13         Debt                                                HTML    106K 
26: R14         Stockholders' Equity                                HTML     43K 
27: R15         Share-Based Compensation                            HTML    133K 
28: R16         Contingent Liabilities                              HTML     33K 
29: R17         Income Taxes                                        HTML    139K 
30: R18         Net Loss Per Share                                  HTML     23K 
31: R19         Industry Segments and Financial Information About   HTML     77K 
                Foreign and Domestic Operations                                  
32: R20         Subsequent Events                                   HTML     26K 
33: R21         Basis of Presentation (Policy)                      HTML    121K 
34: R22         Fair Value Measurements (Tables)                    HTML     50K 
35: R23         Accounts Receivable and Concentration of Credit     HTML     52K 
                Risk (Tables)                                                    
36: R24         Balance Sheet Information (Tables)                  HTML     71K 
37: R25         Intangible Assets and Goodwill (Tables)             HTML     70K 
38: R26         Debt (Tables)                                       HTML     96K 
39: R27         Share-Based Compensation (Tables)                   HTML    125K 
40: R28         Income Taxes (Tables)                               HTML    133K 
41: R29         Industry Segments and Financial Information About   HTML     76K 
                Foreign and Domestic Operations (Tables)                         
42: R30         Basis of Presentation (Narrative) (Details)         HTML     48K 
43: R31         Fair Value Measurements (Narrative) (Details)       HTML     27K 
44: R32         Fair Value Measurements (Reconciliation of the      HTML     28K 
                Beginning and Ending Liability Balance) (Details)                
45: R33         Fair Value Measurements (Schedule of Qualitative    HTML     39K 
                Information) (Details)                                           
46: R34         Accounts Receivable and Concentration of Credit     HTML     58K 
                Risk (Narrative) (Details)                                       
47: R35         Accounts Receivable and Concentration of Credit     HTML     33K 
                Risk (Components Of Accounts Receivable) (Details)               
48: R36         Accounts Receivable and Concentration of Credit     HTML     27K 
                Risk (Summary Of Components Of Allowance For                     
                Doubtful Accounts) (Details)                                     
49: R37         Balance Sheet Information (Components Of            HTML     40K 
                Inventory) (Details)                                             
50: R38         Balance Sheet Information (Schedule of Estimated    HTML     33K 
                Useful Lives of Assets) (Details)                                
51: R39         Balance Sheet Information (Plant and Equipment)     HTML     35K 
                (Details)                                                        
52: R40         Intangible Assets and Goodwill (Narrative)          HTML     31K 
                (Details)                                                        
53: R41         Intangible Assets and Goodwill (Gross Carrying      HTML     43K 
                Amounts of Finite Intangible Assets) (Details)                   
54: R42         Debt (Narrative) (Details)                          HTML     95K 
55: R43         Debt (Credit Agreement) (Details)                   HTML     49K 
56: R44         Debt (Residual Royalty Agreement Liability)         HTML     37K 
                (Details)                                                        
57: R45         Debt (Credit Agreement Interest Expense) (Details)  HTML     33K 
58: R46         Stockholders' Equity (Narrative) (Details)          HTML    113K 
59: R47         Share-Based Compensation (Narrative) (Details)      HTML     84K 
60: R48         Share-Based Compensation (Recorded Share-Based      HTML     32K 
                Compensation Expenses) (Details)                                 
61: R49         Share-Based Compensation (Weighted Average          HTML     35K 
                Assumptions For Options Granted) (Details)                       
62: R50         Share-Based Compensation (Summary Of Stock Options  HTML     59K 
                Outstanding And Exercisable) (Details)                           
63: R51         Contingent Liabilities (Narrative) (Details)        HTML     25K 
64: R52         Income Taxes (Narrative) (Details)                  HTML     44K 
65: R53         Income Taxes (Reconciliation Of Income Tax Expense  HTML     49K 
                (Benefit)) (Details)                                             
66: R54         Income Taxes (Significant Components Of Deferred    HTML     78K 
                Tax Assets And Liabilities) (Details)                            
67: R55         Income Taxes (Schedule Of Deferred Tax Amounts      HTML     33K 
                Classified In Balance Sheets) (Details)                          
68: R56         Industry Segments and Financial Information About   HTML     44K 
                Foreign and Domestic Operations (Schedule of                     
                Segment Reporting Information) (Details)                         
69: R57         Subsequent Events (Narrative) (Details)             HTML     29K 
71: XML         IDEA XML File -- Filing Summary                      XML    130K 
70: EXCEL       IDEA Workbook of Financial Reports                  XLSX     88K 
 7: EX-101.INS  XBRL Instance -- veru-20190331                       XML   1.99M 
 9: EX-101.CAL  XBRL Calculations -- veru-20190331_cal               XML    140K 
10: EX-101.DEF  XBRL Definitions -- veru-20190331_def                XML    491K 
11: EX-101.LAB  XBRL Labels -- veru-20190331_lab                     XML   1.02M 
12: EX-101.PRE  XBRL Presentations -- veru-20190331_pre              XML    826K 
 8: EX-101.SCH  XBRL Schema -- veru-20190331                         XSD    152K 
72: ZIP         XBRL Zipped Folder -- 0000863894-19-000007-xbrl      Zip    158K

‘EX-101.CAL’   —   XBRL Calculations — veru-20190331_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created by Certent Disclosure Management 6.28.0.1 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 5/15/2019 1:10:44 PM -->
<!-- Modified on: 5/15/2019 1:10:44 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://verupharma.com/role/StatementCondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#DisclosureAccountsReceivableAndConcentrationOfCreditRiskComponentsOfAccountsReceivableDetails" roleURI="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRiskComponentsOfAccountsReceivableDetails"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#DisclosureBalanceSheetInformationComponentsOfInventoryDetails" roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformationComponentsOfInventoryDetails"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#DisclosureBalanceSheetInformationPlantAndEquipmentDetails" roleURI="http://verupharma.com/role/DisclosureBalanceSheetInformationPlantAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" roleURI="http://verupharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"/>
<roleRef xlink:type="simple" xlink:href="veru-20190331.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://verupharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"/>
<calculationLink xlink:role="http://verupharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_636935226416875548" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636935226416875548" xlink:to="us-gaap_Cash_636935226416875548" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636935226416875548" xlink:to="us-gaap_AccountsReceivableNetCurrent_636935226416875548" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636935226416875548" xlink:to="us-gaap_InventoryNet_636935226416875548" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636935226416875548" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636935226416875548" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_636935226416875548" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_636935226416875548" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_636935226416875548" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636935226416875548" order="5" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_636935226416875548"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_636935226416875548" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636935226416885535" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="us-gaap_LiabilitiesCurrent_636935226416885535" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636935226416885535" xlink:to="us-gaap_AccountsPayableCurrent_636935226416885535" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636935226416885535" xlink:to="us-gaap_OtherLiabilitiesCurrent_636935226416885535" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636935226416885535" xlink:to="us-gaap_LinesOfCreditCurrent_636935226416885535" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636935226416885535" xlink:to="us-gaap_DeferredRevenueCurrent_636935226416885535" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="veru_AccruedResearchAndDevelopmentCostsCurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636935226416885535" xlink:to="veru_AccruedResearchAndDevelopmentCostsCurrent_636935226416885535" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="us-gaap_DeferredRentCreditNoncurrent_636935226416885535" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_ResidualRoyaltyAgreementNoncurrent" xlink:label="veru_ResidualRoyaltyAgreementNoncurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="veru_ResidualRoyaltyAgreementNoncurrent_636935226416885535" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="us-gaap_LongTermLineOfCredit_636935226416885535" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636935226416885535" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636935226416885535" xlink:to="us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_636935226416885535" order="6" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636935226416885535"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636935226416885535" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636935226416885535" xlink:to="us-gaap_CommonStockValue_636935226416895503" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636935226416885535" xlink:to="us-gaap_AdditionalPaidInCapital_636935226416895503" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636935226416885535" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636935226416895503" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636935226416885535" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636935226416895503" order="4" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636935226416885535" xlink:to="us-gaap_TreasuryStockValue_636935226416895503" order="5" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements Of Operations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636796815397626942"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636796815397626942" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636935226416895503" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636935226416895503" xlink:to="us-gaap_NonoperatingIncomeExpense_636935226416895503" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_636935226416895503" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636935226416895503" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_636935226416895503" xlink:to="us-gaap_InterestExpense_636935226416895503" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_636935226416895503" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_636935226416895503" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_636935226416895503" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636935226416895503" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636935226416895503" xlink:to="us-gaap_OperatingIncomeLoss_636935226416895503" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636935226416895503" xlink:to="us-gaap_GrossProfit_636935226416895503" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636935226416895503" xlink:to="us-gaap_CostOfGoodsAndServicesSold_636935226416895503" order="1" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_636935226416895503"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636935226416895503" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_636935226416895503" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636935226416895503" xlink:to="us-gaap_OperatingExpenses_636935226416905472" order="2" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636935226416905472" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_636935226416905472" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636935226416905472" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_636935226416905472" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636935226416905472" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636935226416905472" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636796815397626942" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636935226416905472" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements Of Cash Flows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_NetIncomeLoss_636935226416905472" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_636935226416905472" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_AmortizationOfIntangibleAssets_636935226416905472" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_OtherNoncashIncomeExpense_636935226416905472" order="4" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_636935226416905472" order="5" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_636935226416905472" order="6" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_ShareBasedCompensation_636935226416905472" order="7" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_636935226416905472" order="8" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636935226416905472" order="9" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_636935226416905472" order="10" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636935226416905472" order="11" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636935226416905472"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInInventories_636935226416905472" order="12" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636935226416915500" order="13" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_DepreciationAndOtherAmortization" xlink:label="veru_DepreciationAndOtherAmortization_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="veru_DepreciationAndOtherAmortization_636935226416915500" order="14" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636935226416905472" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_636935226416915500" order="15" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636935226416915500" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636935226416915500" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636935226416915500" order="1" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636935226416915500" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636935226416915500" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_636935226416915500" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_636935226416915500" order="4" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_636935226416915500"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636935226416915500" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_636935226416915500" order="5" use="optional" weight="-1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/DisclosureAccountsReceivableAndConcentrationOfCreditRiskComponentsOfAccountsReceivableDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Accounts Receivable and Concentration of Credit Risk (Components Of Accounts Receivable) (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_636854154296190567"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet_636854154296190567" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_636935226416925415" order="1" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet_636854154296190567" xlink:to="us-gaap_AccountsReceivableGross_636935226416925415" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_AllowanceForSalesAndPaymentTermDiscounts" xlink:label="veru_AllowanceForSalesAndPaymentTermDiscounts_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet_636854154296190567" xlink:to="veru_AllowanceForSalesAndPaymentTermDiscounts_636935226416925415" order="3" use="optional" weight="-1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/DisclosureBalanceSheetInformationComponentsOfInventoryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Information (Components Of Inventory) (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross_636935226416925415" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross_636935226416925415" xlink:to="us-gaap_InventoryRawMaterials_636935226416925415" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross_636935226416925415" xlink:to="us-gaap_InventoryWorkInProcess_636935226416925415" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross_636935226416925415" xlink:to="us-gaap_InventoryFinishedGoods_636935226416925415" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves_636935226416925415" order="2" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/DisclosureBalanceSheetInformationPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Balance Sheet Information (Plant and Equipment) (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636935226416925415" order="1" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636935226416925415" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes (Reconciliation Of Income Tax Expense (Benefit)) (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_636935226416925415" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_636935226416925415" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_636935226416925415" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_636935226416925415" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_636935226416925415" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_636935226416925415" order="6" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_636935226416925415" order="7" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_IncomeTaxReconciliationEffectOfDeemedDividends" xlink:label="veru_IncomeTaxReconciliationEffectOfDeemedDividends_636935226416925415"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="veru_IncomeTaxReconciliationEffectOfDeemedDividends_636935226416925415" order="8" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://verupharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes (Significant Components Of Deferred Tax Assets And Liabilities) (Details)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_636935226416935399" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_636935226416935399" xlink:to="us-gaap_DeferredTaxAssetsGross_636935226416935399" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_636935226416935399" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636935226416935399" order="2" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_636935226416935399" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_DeferredTaxLiabilitiesInProcessRAndD" xlink:label="veru_DeferredTaxLiabilitiesInProcessRAndD_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399" xlink:to="veru_DeferredTaxLiabilitiesInProcessRAndD_636935226416935399" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="veru-20190331.xsd#veru_DeferredTaxLiabilitiesDevelopedTechnology" xlink:label="veru_DeferredTaxLiabilitiesDevelopedTechnology_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399" xlink:to="veru_DeferredTaxLiabilitiesDevelopedTechnology_636935226416935399" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_636935226416935399"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_636935226416935399" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_636935226416935399" order="4" use="optional" weight="1" priority="2"/>
</calculationLink>
</linkbase>

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/24  Veru Inc.                         10-K/A      9/30/23   96:18M
12/08/23  Veru Inc.                         10-K        9/30/23   88:14M
12/05/22  Veru Inc.                         10-K        9/30/22   87:13M
12/02/21  Veru Inc.                         10-K        9/30/21   96:9.5M
12/10/20  Veru Inc.                         10-K        9/30/20  100:9.9M
↑Top
Filing Submission 0000863894-19-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 11, 9:17:54.2pm ET